The anti-tumour activity of TRAIL has been investigated in haematological malignancies, including multiple myeloma cells and Philadelphia chromosome-positive leukaemia, in which TRAIL was shown to be able to induce apoptosis [15, 16]. This evidence concerns the gene TNFSF10 and plasma cell myeloma.